cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on
ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple
myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors.
Harpoon has also developed a proprietary ProTriTAC(TM) platform, which applies a prodrug concept to its TriTAC platform
to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information
about Harpoon Therapeutics, please visit www.harpoontx.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Words such as "may," "will," "expect," "plan," "potential," "anticipate," "target," "estimate," "intend"
and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon
Therapeutics' expectations and assumptions as of the date of this press release. Each of these forward-looking
statements involves risks and uncertainties that could cause Harpoon Therapeutics' clinical development programs,
future results or performance to differ significantly from those expressed or implied by the forward-looking
statements. Forward-looking statements contained in this press release include, but are not limited to, statements
about the anticipated progress, timing, scope and results of preclinical and clinical trials, the association of data
with potential treatment outcomes, the development and advancement of product candidates, planned additional clinical
testing and development efforts for its product candidates and the timing thereof, and other statements that are not
historical fact. Many factors may cause differences between current expectations and actual results, including
unexpected safety or efficacy data observed during clinical studies, that preliminary data and trends may not be
predictive of future data or results, may not demonstrate safety or efficacy or lead to regulatory approval by the FDA
or other regulatory agencies; clinical trial site activation or enrollment rates that are lower than expected,
unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing
competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process,
the timing and results of unexpected litigation or other disputes, and the sufficiency of Harpoon Therapeutics' cash
resources. These and other factors that may cause Harpoon Therapeutics' actual results to differ from those expressed
or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics' filings with
the U.S. Securities and Exchange Commission, including under "Risk Factors" in Harpoon Therapeutics' quarterly report
on Form 10-Q for the quarter ended March 31, 2021 and future filings by Harpoon Therapeutics. Except as required by
law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes available.
Contacts:
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com
Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 109497
EQS News ID: 1204616
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1204616&application_name=news
(END) Dow Jones Newswires
June 04, 2021 10:25 ET (14:25 GMT)